热门资讯> 正文
Capricor Therapeutics与Nippon Shinyaku合作，在欧洲商业化Deramiocel
2024-09-17 21:41
- Capricor Therapeutics (NASDAQ:CAPR) entered into a binding term sheet with Nippon Shinyaku, a Japanese pharmaceutical company, for the commercialization and distribution in Europe of Capricor’s lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy.
- Nippon Shinyaku has agreed to purchase about $15M of Capricor common stock at a 20% premium to the 60-day VWAP.
- Capricor will be responsible for the development and manufacturing of deramiocel for potential approval in all countries in the European Union, United Kingdom and several other countries in the region.
- Capricor will also receive an upfront payment of $20M subject to execution of the agreement and there are potential additional development and sales-based milestone payments to Capricor of up to $715M and Capricor will receive a double-digit share of product revenue.
- Source: Press Release
More on Capricor Therapeutics
- Capricor Therapeutics, Inc. (CAPR) Q2 2024 Earnings Call Transcript
- Capricor Therapeutics Q2 2024 Earnings Preview
- Capricor gains FDA pre-BLA meeting on deramiocel for Duchenne muscular dystrophy
- Seeking Alpha’s Quant Rating on Capricor Therapeutics
- Historical earnings data for Capricor Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
